Literature DB >> 27271567

HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.

Ashley M Kilcollins1, Jin Li2, Chia-Hung Christine Hsiao2, Andrew J Wiemer3.   

Abstract

Vγ9Vδ2 effector T cells lyse cells in response to phosphorus-containing small molecules, providing primates a unique route to remove infected or malignant cells. Yet, the triggering mechanisms remain ill defined. We examined lysis mediated by human Vγ9Vδ2 effector T cells in response to the naturally occurring (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) or a synthetic cell-permeable prodrug, bis (pivaloyloxymethyl) (E)-4-hydroxy-3-methyl-but-2-enyl phosphonate. CD27(+)/CD45RA(-) Th1-like effector cells killed K562 target cells through a mechanism that could be enhanced by either compound or TCR Ab and blocked by Src inhibition or butyrophilin 3 isoform A1 (BTN3A1) disruption. Pretreatment at 4 °: C decreased HMBPP-induced lysis but did not reduce lysis induced by bis (pivaloyloxymethyl) (E)-4-hydroxy-3-methyl-but-2-enyl phosphonate. Together, our results show that internalization of HMBPP into target cells is required for BTN3A1-dependent lysis by Vγ9Vδ2 effector T cells. The enhanced activity of the prodrug analog is due to its ability to bypass the pathways required for entry of HMBPP. These findings support an inside-out model of T cell triggering driven by small-molecule induction of BTN3A1.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27271567      PMCID: PMC4935553          DOI: 10.4049/jimmunol.1501833

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.

Authors:  H J Harwood; I M Alvarez; W D Noyes; P W Stacpoole
Journal:  J Lipid Res       Date:  1991-08       Impact factor: 5.922

Review 2.  Human gamma delta T cells: Evolution and ligand recognition.

Authors:  Erin J Adams; Siyi Gu; Adrienne M Luoma
Journal:  Cell Immunol       Date:  2015-05-06       Impact factor: 4.868

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

4.  High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.

Authors:  Ismahène Benzaïd; Hannu Mönkkönen; Verena Stresing; Edith Bonnelye; Jonathan Green; Jukka Mönkkönen; Jean-Louis Touraine; Philippe Clézardin
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

5.  Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.

Authors:  Keith Thompson; Michael J Rogers; Fraser P Coxon; Julie C Crockett
Journal:  Mol Pharmacol       Date:  2006-02-24       Impact factor: 4.436

6.  Differential role for CD277 as a co-regulator of the immune signal in T and NK cells.

Authors:  Nassima Messal; Emilie Mamessier; Aude Sylvain; Javier Celis-Gutierrez; Marie-Laure Thibult; Bruno Chetaille; Guylène Firaguay; Sonia Pastor; Yves Guillaume; Qian Wang; Ivan Hirsch; Jacques A Nunès; Daniel Olive
Journal:  Eur J Immunol       Date:  2011-11-03       Impact factor: 5.532

7.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

8.  Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6.

Authors:  Felipe Riaño; Mohindar M Karunakaran; Lisa Starick; Jianqiang Li; Claus J Scholz; Volker Kunzmann; Daniel Olive; Sabine Amslinger; Thomas Herrmann
Journal:  Eur J Immunol       Date:  2014-06-30       Impact factor: 5.532

9.  Interaction of phospholipid vesicles with cells. Endocytosis and fusion as alternate mechanisms for the uptake of lipid-soluble and water-soluble molecules.

Authors:  S Batzri; E D Korn
Journal:  J Cell Biol       Date:  1975-09       Impact factor: 10.539

10.  Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion.

Authors:  D Kozbor; G Trinchieri; D S Monos; M Isobe; G Russo; J A Haney; C Zmijewski; C M Croce
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  23 in total

1.  A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.

Authors:  Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2018-11-02       Impact factor: 5.858

2.  Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.

Authors:  Benjamin J Foust; Jin Li; Chia-Hung Christine Hsiao; David F Wiemer; Andrew J Wiemer
Journal:  ChemMedChem       Date:  2019-07-24       Impact factor: 3.466

3.  The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.

Authors:  Khiem Nguyen; Jin Li; Robbins Puthenveetil; Xiaochen Lin; Michael M Poe; Chia-Hung Christine Hsiao; Olga Vinogradova; Andrew J Wiemer
Journal:  FASEB J       Date:  2017-07-13       Impact factor: 5.191

Review 4.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

5.  Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.

Authors:  Morgane Moulin; Javier Alguacil; Siyi Gu; Asmaa Mehtougui; Erin J Adams; Suzanne Peyrottes; Eric Champagne
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

6.  Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.

Authors:  Nicholas A Lentini; Benjamin J Foust; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  J Med Chem       Date:  2018-09-26       Impact factor: 7.446

7.  Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.

Authors:  Rebekah R Shippy; Xiaochen Lin; Sherry S Agabiti; Jin Li; Brendan M Zangari; Benjamin J Foust; Michael M Poe; Chia-Hung Christine Hsiao; Olga Vinogradova; David F Wiemer; Andrew J Wiemer
Journal:  J Med Chem       Date:  2017-03-01       Impact factor: 7.446

8.  Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.

Authors:  Benjamin J Foust; Michael M Poe; Nicholas A Lentini; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2017-08-09       Impact factor: 4.345

9.  BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Audrey Benyamine; Céline Loncle; Etienne Foucher; Juan-Luis Blazquez; Céline Castanier; Anne-Sophie Chrétien; Mauro Modesti; Véronique Secq; Salem Chouaib; Meritxell Gironella; Elena Vila-Navarro; Giuseppe Montalto; Jean-Charles Dagorn; Nelson Dusetti; Juan Iovanna; Daniel Olive
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

10.  BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.

Authors:  Mahboob Salim; Timothy J Knowles; Alfie T Baker; Martin S Davey; Mark Jeeves; Pooja Sridhar; John Wilkie; Carrie R Willcox; Hachemi Kadri; Taher E Taher; Pierre Vantourout; Adrian Hayday; Youcef Mehellou; Fiyaz Mohammed; Benjamin E Willcox
Journal:  ACS Chem Biol       Date:  2017-09-14       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.